Cynata Therapeutics (CYP) Stock Price, News & Analysis

Company Overview

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 159,853 shs
• Average Volume: N/A
• Market Capitalization: A$57.60 million
• P/E Ratio: N/A
• Dividend Yield: 13.95%
• Price Target: N/A
• Consensus Rating: N/A

CYP Stock Analysis - Frequently Asked Questions

How were Cynata Therapeutics' earnings last quarter?

Cynata Therapeutics Limited (ASX:CYP) announced its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). Cynata Therapeutics had a negative trailing twelve-month return on equity of 100.01% and a negative net margin of 420.82%.

What other stocks do shareholders of Cynata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cynata Therapeutics investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Bank of America (BAC), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU) and Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund (ETO).

Company Calendar

• Last Earnings: 2/27/2019
• Today: 9/14/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:CYP
• CIK: N/A
• Web: www.cynata.com
• Phone: 61 3 9824 5254
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$9.74 million
• Net Margins: -420.82%
• Pretax Margin: N/A
• Return on Equity: -100.01%
• Return on Assets: -46.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.58
• Quick Ratio: 9.23

Sales & Book Value

• Annual Sales: A$2.32 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 11.93
• Book Value: A$0.04 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 180,680,000
• Free Float: N/A
• Market Cap: A$57.60 million
• Optionable: Not Optionable
• Beta: 0.93